Literature DB >> 27842890

New small 99mTc-labeled peptides for HER2 receptor imaging.

Hamideh Sabahnoo1, Zohreh Noaparast1, Seyed Mohammad Abedi2, Seyed Jalal Hosseinimehr3.   

Abstract

The high expression of the human epidermal growth factor receptor 2 (HER2) and the accessibility of its extracellular domain make it an ideal target for the targeted delivery of anti-tumor drugs as well as imaging agents. In this study, the heptapeptide leucine-threonine-valine-serine-proline-tryptophan-tyrosine (LTVSPWY) as a new small peptide for an anti-HER2 target was labeled by incorporating 99mTc to the cysteine-based ligands CGGG (Cys-Gly-Gly-Gly) and CSSS (Cys-Ser-Ser-Ser) linked to this peptide. Both 99mTc-labeled peptides were evaluated for HER2 bindings as well as pharmacokinetics and tumor targeting. CGGG- and CSSS-LTVSPWY peptides were labeled with 99mTc using a gluconate ligand exchange. Cellular specific binding, affinities, and internalization of both peptides to the HER2 receptor were evaluated in the SKOV-3 cell line. Specific targeting of both peptides to the HER2 receptor was assessed in three cell lines with different levels of HER2 expression. Studies were performed in SKOV-3 tumor bearing mice for tumor targeting. Both peptides were labeled with 99mTc with more than 99% efficiency and showed favorable stability in solution and serum. The HER2 binding affinities of both the radiolabeled peptides were inhibited up to 60% by the unlabeled peptide, as well as with trastuzumab antibody. We observed nanomolar binding affinities for both radiolabeled peptides. The tumor uptakes were 4.95 ± 4.84% and 3.84 ± 2.53% for the CSSS and CGGG chelators, respectively, at 1 h after injection. However, tumor uptakes were similar for both peptides at 4 h postinjection, although a higher tumor to background ratio and lower radioactivity retention in the kidney were observed for CSSS, leading to a clearer tumor image with injection of this peptide. These small new peptides were selectively targeted to the HER2 receptor, and introduction of a serine residue into the chelator improved the pharmacokinetics of 99mTc labeled LTVSPWY for clear tumor imaging in animals.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  (99m)Tc; Cysteine-based ligand; HER2 receptor; LTVSPWY; Peptide; Tumor uptake

Mesh:

Substances:

Year:  2016        PMID: 27842890     DOI: 10.1016/j.ejmech.2016.11.011

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

1.  Homodimer 99mTc-HYNIC-E(SSSLTVPWY)2 peptide improved HER2-overexpressed tumor targeting and imaging.

Authors:  Fatemeh Ebrahimi; Zohreh Noaparast; Seyed Mohammad Abedi; Seyed Jalal Hosseinimehr
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

Review 2.  Targeting HER2 in Nuclear Medicine for Imaging and Therapy.

Authors:  Adriana V F Massicano; Bernadette V Marquez-Nostra; Suzanne E Lapi
Journal:  Mol Imaging       Date:  2018 Jan-Dec       Impact factor: 4.488

3.  Novel Linear Peptides with High Affinity to αvβ3 Integrin for Precise Tumor Identification.

Authors:  Yi Ma; Guanhua Ai; Congying Zhang; Menglu Zhao; Xue Dong; Zhihao Han; Zhaohui Wang; Min Zhang; Yuxi Liu; Weidong Gao; Siwen Li; Yueqing Gu
Journal:  Theranostics       Date:  2017-04-06       Impact factor: 11.556

Review 4.  PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.

Authors:  Sara S Rinne; Anna Orlova; Vladimir Tolmachev
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

Review 5.  Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides.

Authors:  Shushan Ge; Jihui Li; Yu Yu; Zhengguo Chen; Yi Yang; Liqing Zhu; Shibiao Sang; Shengming Deng
Journal:  Molecules       Date:  2021-10-27       Impact factor: 4.411

6.  Synthesis and comparative evaluation of 177Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes.

Authors:  Amit Kumar Sharma; Rohit Sharma; Kusum Vats; Haladhar Dev Sarma; Archana Mukherjee; Tapas Das; Drishty Satpati
Journal:  Sci Rep       Date:  2022-09-20       Impact factor: 4.996

7.  99mTc-HYNIC-(tricine/EDDA)-FROP peptide for MCF-7 breast tumor targeting and imaging.

Authors:  Sajjad Ahmadpour; Zohreh Noaparast; Seyed Mohammad Abedi; Seyed Jalal Hosseinimehr
Journal:  J Biomed Sci       Date:  2018-02-19       Impact factor: 8.410

8.  Peptide Based Imaging Agents for HER2 Imaging in Oncology.

Authors:  Maxwell Ducharme; Suzanne E Lapi
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.